SavedAdd your journal

Journals / Turkish Journal of Pharmaceutical Sciences / 2017 / Cilt: 14 - Sayı: 1

Flavin İçeren Monooksijenazlar ve Ksenobiyotiklerin Metabolizması

Flavin Containing Monooxygenases and Metabolism of Xenobiotics

Rahman BAŞARAN
Benay CAN-EKE
Pages
90–94
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Future studies on FMOs may provide considerable information about the pathophysiology of diseases and the information related to this enzyme family may be important for drug designs in future.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:This review summarizes recent information concerning the pharmacological and toxicological significance of the flavin-containing monooxygenases (FMOs).
📊
Key Findings & Data:FMOs are a family of microsomal enzymes involving in the oxygenation of certain xenobiotics and drugs containing nucleophilic heteroatoms.
💡
Conclusion & Impact:Future studies on FMOs may provide considerable information about the pathophysiology of diseases and the information related to this enzyme family may be important for drug designs in future.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

This review summarizes recent information concerning the pharmacological and toxicological significance of the flavin-containing monooxygenases (FMOs). FMOs are a family of microsomal enzymes involving in the oxygenation of certain xenobiotics and drugs containing nucleophilic heteroatoms. The activities of FMOs in drug metabolism and their relationships with diseases are the areas of research requiring further exploration. Future studies on FMOs may provide considerable information about the pathophysiology of diseases and the information related to this enzyme family may be important for drug designs in future.

Özet

Bu derlemede flavin-içeren monooksijenazların (FMO) farmakolojik ve toksikolojik önemi ile ilgili güncel bilgiler özetlenmiştir. FMO'lar nükleofilik hetereatom içeren ksenobiyotiklerin ve ilaçların oksidasyonuna katılan mikrozomal bir enzim ailesidir. FMO'ların ilaç metabolizmasındaki etkinlikleri ve hastalıklarla olan ilişkileri, daha fazla araştırılması gereken alanlardır. FMO'lar üzerine yapılacak olan araştırmalar hastalıkların patofizyolojisi hakkında önemli bilgiler sağlayabilir ve bu enzim ailesi ile ilgili bilgiler gelecekte, ilaç tasarımları için önemli olabilir.

🔖

Cite This Article

BAŞARAN, R., CAN-EKE, B. (2017). Flavin İçeren Monooksijenazlar ve Ksenobiyotiklerin Metabolizması. Turkish Journal of Pharmaceutical Sciences, Cilt: 14 - Sayı: 1, 90–94. https://ajindex.com/articles/403694

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Katzung BG, Basic & Clinical Pharmacology (9th ed.) NY: Lange Medical Books/McGraw Hill, 2004
  2. Ziegler DM, Mitchell CH. Microsomal oxidase IV: properties of mixedfunction amine oxidase isolated from pig liver microsomes. Arch Biochem Biophys. 1972;150:116-125
  3. Ziegler DM, Poulsen LL. Hepatic microsomal mixed-function amine oxidase. Methods Enzymol. 1978;52:142-151
  4. Tynes RE, Sabourin PJ, Hodgson E. Identifi-cation of distrinct hepatic and pulmonary forms of microsomal flaving-containing monooxyge-nase in the mouse and rabbit. Biochem Biophys Res Commun. 1985;126:1069-1075
  5. Cashman JR, Zhang J. Interindividual diffe-rences of human flavincontaining mono-oxygenase 3: genetic polymorphisms and functional variation. Drug Metab Dispos. 2002;30:1043-1052
  6. Cashman JR. Structural and catalytic properties of the mammalian flavin-containing mono-oxygenase. Chem Res Toxicol. 1995;8:166-181
  7. Testa B, Pedretti A, Vistoli G. Reactions and enzymes in the metabolism of drugs and other xenobiotics. Drug Discov Today. 2012;17:549-560
  8. Cruciani G, Valeri A, Goracci L, Pellegrino RM, Buonerba F, Baroni M. Flavin monooxygenase metabolism: Why medicinal chemists should matter. J Med Chem. 2014;57:6183-6196
  9. Hodgson E, Blake BL, Levi PE, Mailman RB, Lawton MP, Philpot RM, Genter MB, Flavin-containing monooxygenases: substrate specificity and complex metabolic pathways, In Molecular Aspects of Oxidative Drug Metabolizing Enzymes: Their significance in Environmental Toxicology, Chemical Carcinogenesis and Health, Nato ASI Series, pp 225-235, Plenum Publishers, New York. 1995
  10. Poulsen LL, Ziegler DM. Multisubstrate flavin-containing monooxygenases: applications of mechanism to specificity. Chem Biol Interact. 1995;96:57-73
  11. Kousba A, Soll R, Yee S, Martin M. Cyclic conversion of the novel SRC kinase inhibitor [7-(2,6- dichloro-phenyl)-5-methyl-benzo[1,2, 4] triazin-3-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl] amine (TG100435) and its N-oxide metabolite by flavin-containing monoxygena-ses and cytochrome P450 reductase. Drug Metab Dispos. 2007;35:2242-2251
  12. Adali O, Carver GC, Philpot RM. Modulation of human flavin containing monooxygenase 3 activity by tricyclic antidepressants and other agents: Importance of residue 428. Arch Biochem Biophys. 1998;358:92-97
  13. Krueger SK, Williams DE. Mammalian flavin-containing monooxygenases: structure function, genetic polymorphisms and role in drug metabolism. Pharmacol Ther. 2005;106:357-387
  14. Hines R